Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Post-acute or prolonged COVID-19: ivermectin treatment for patients with persistent symptoms or post-acute symptoms

Chang et al., ResearchGate
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Report on 33 patients with persistent or post-acute symptoms treated with ivermectin, showing a high rate of clinical improvement.
Chang et al., 31 Jul 2020, preprint, 4 authors.
This PaperIvermectinAll
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/344318845 POST-ACUTE OR PROLONGED COVID-19: IVERMECTIN TREATMENT FOR PATIENTS WITH PERSISTENT SYMPTOMS OR POST-ACUTE Preprint · July 2020 CITATIONS READS 0 98,767 5 authors, including: Gustavo Aguirre Chang Manuel Yui National University of San Marcos Instituto Nacional de Oftalmología - Peru 118 PUBLICATIONS 82 CITATIONS 4 PUBLICATIONS 3 CITATIONS SEE PROFILE SEE PROFILE Aurora Natividad Trujillo Figueredo José Aníbal Córdova Masías SIGESA Instituto nacional de ciencias Neurológicas, Lima, Perú 107 PUBLICATIONS 23 CITATIONS 11 PUBLICATIONS 18 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: COVID 19 View project COVID POR VARIANTES DEL SARS COV-2 View project All content following this page was uploaded by Gustavo Aguirre Chang on 22 October 2020. The user has requested enhancement of the SEE PROFILE POST-ACUTE OR PROLONGED COVID-19: TREATMENT WITH IVERMECTIN FOR PATIENTS WITH PERSISTENT, OR POST-ACUTE SYMPTOMS Aguirre-Chang, Gustavo; Castillo Saavedra, Eduardo; Yui Cerna, Manuel; Trujillo Figueredo, Aurora; Córdova Masías, José. Reseach Gate. July 11, 2020. English translation copy edited by Madeline Oh SUMMARY INTRODUCTION: It is estimated that between 10 to 45% of people who become ill with COVID-19 will present with symptoms after the acute stage of the disease. These symptoms will persist for weeks, developing what is called Persistent or Post-Acute Symptoms of COVID- 19. There is no consensus, nor has there been a publication on specific and effective treatment for these cases. Knowledge is quite lacking as to its etiopathogenesis. MATERIAL AND METHODS: 33 patients with Persistent or Post-Acute Symptoms of COVID-19, who were between weeks 4 and 12 from the onset of symptoms were enrolled in the present study. Patients whose main symptoms were musculoskeletal such as fatigue due to muscle weakness, diminished muscle strength and myalgia (muscle pain) were excluded. The following protocol was followed: in cases with mild symptoms, Ivermectin was administered at a dose of 0.2 mg per kilogram of body weight per day for 2 days. If patients still had symptoms after the 2 doses, 2 additional days of Ivermectin treatment were given at the same dose. For cases with moderate symptoms, a dose of 0.4 mg per kilogram of body weight was prescribed for 2 days, followed by 0.2 mg per kilogram of body weight for 2 additional days. If a patient continued to have symptoms after the fourth day of treatment, more doses of Ivermectin were indicated. Treatment then continued for additional days until either clinical improvement was observed, or there was no longer further clinical improvement with treatment. RESULTS: 33 adult patients with Persistent or Post-Acute Symptoms of COVID-19 were treated with Ivermectin. In 94% of the 33 patients, clinical improvement to some degree (partial or total) was observed after 2 doses of Ivermectin. Total improvement (without any symptoms) was observed in 87.9% of the patients after the 2 daily doses of Ivermectin. In 12.1% of patients whose symptoms had not been completely resolved after the first 2 doses, additional doses of Ivermectin treatment were administered according to the protocol, and total clinical resolution of symptoms was observed in 94% of cases. CONCLUSION: The result of the present study..
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit